OTCMKTS:XCRP

Xcorporeal Competitors

$0.0030
0.00 (0.00 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.00
Now: $0.00
$0.00
50-Day Range
$0.00
MA: $0.01
$0.01
52-Week Range
$0.00
Now: $0.00
$0.07
VolumeN/A
Average Volume6,200 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta3.62

Competitors

Xcorporeal (OTCMKTS:XCRP) Vs. MDT, SONVY, VAR, MASI, GNGBY, and LIVN

Should you be buying XCRP stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Xcorporeal, including Medtronic (MDT), Sonova (SONVY), Varian Medical Systems (VAR), Masimo (MASI), Getinge (GNGBY), and LivaNova (LIVN).

Xcorporeal (OTCMKTS:XCRP) and Medtronic (NYSE:MDT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.

Profitability

This table compares Xcorporeal and Medtronic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
XcorporealN/AN/AN/A
Medtronic12.69%9.71%5.30%

Insider & Institutional Ownership

79.2% of Medtronic shares are held by institutional investors. 0.5% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Xcorporeal has a beta of 3.62, indicating that its share price is 262% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Xcorporeal and Medtronic, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Xcorporeal0000N/A
Medtronic031812.91

Medtronic has a consensus price target of $124.2692, suggesting a potential upside of 0.30%. Given Medtronic's higher possible upside, analysts plainly believe Medtronic is more favorable than Xcorporeal.

Valuation & Earnings

This table compares Xcorporeal and Medtronic's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XcorporealN/AN/AN/AN/AN/A
Medtronic$28.91 billion5.78$4.79 billion$4.5926.99

Medtronic has higher revenue and earnings than Xcorporeal.

Summary

Medtronic beats Xcorporeal on 9 of the 10 factors compared between the two stocks.

Xcorporeal (OTCMKTS:XCRP) and Sonova (OTCMKTS:SONVY) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Profitability

This table compares Xcorporeal and Sonova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
XcorporealN/AN/AN/A
SonovaN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Xcorporeal and Sonova, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Xcorporeal0000N/A
Sonova06302.33

Institutional & Insider Ownership

1.1% of Sonova shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Xcorporeal has a beta of 3.62, meaning that its stock price is 262% more volatile than the S&P 500. Comparatively, Sonova has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

Earnings and Valuation

This table compares Xcorporeal and Sonova's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XcorporealN/AN/AN/AN/AN/A
Sonova$2.96 billion6.18$489.96 million$1.4938.08

Sonova has higher revenue and earnings than Xcorporeal.

Summary

Sonova beats Xcorporeal on 3 of the 4 factors compared between the two stocks.

Xcorporeal (OTCMKTS:XCRP) and Varian Medical Systems (NYSE:VAR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, institutional ownership, profitability and dividends.

Institutional and Insider Ownership

87.0% of Varian Medical Systems shares are owned by institutional investors. 0.8% of Varian Medical Systems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for Xcorporeal and Varian Medical Systems, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Xcorporeal0000N/A
Varian Medical Systems35001.63

Varian Medical Systems has a consensus target price of $159.3571, indicating a potential downside of 10.00%. Given Varian Medical Systems' higher probable upside, analysts clearly believe Varian Medical Systems is more favorable than Xcorporeal.

Risk and Volatility

Xcorporeal has a beta of 3.62, meaning that its stock price is 262% more volatile than the S&P 500. Comparatively, Varian Medical Systems has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500.

Profitability

This table compares Xcorporeal and Varian Medical Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
XcorporealN/AN/AN/A
Varian Medical Systems8.50%18.45%8.08%

Earnings and Valuation

This table compares Xcorporeal and Varian Medical Systems' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XcorporealN/AN/AN/AN/AN/A
Varian Medical Systems$3.17 billion5.13$269.20 million$3.9145.29

Varian Medical Systems has higher revenue and earnings than Xcorporeal.

Summary

Varian Medical Systems beats Xcorporeal on 7 of the 8 factors compared between the two stocks.

Masimo (NASDAQ:MASI) and Xcorporeal (OTCMKTS:XCRP) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Institutional & Insider Ownership

81.6% of Masimo shares are owned by institutional investors. 11.5% of Masimo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Masimo and Xcorporeal's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Masimo$937.84 million14.12$196.22 million$3.2274.39
XcorporealN/AN/AN/AN/AN/A

Masimo has higher revenue and earnings than Xcorporeal.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Masimo and Xcorporeal, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Masimo02502.71
Xcorporeal0000N/A

Masimo currently has a consensus target price of $272.20, suggesting a potential upside of 13.63%. Given Masimo's higher possible upside, analysts plainly believe Masimo is more favorable than Xcorporeal.

Volatility & Risk

Masimo has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Xcorporeal has a beta of 3.62, suggesting that its stock price is 262% more volatile than the S&P 500.

Profitability

This table compares Masimo and Xcorporeal's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Masimo20.30%15.75%13.12%
XcorporealN/AN/AN/A

Summary

Masimo beats Xcorporeal on 8 of the 9 factors compared between the two stocks.

Getinge (OTCMKTS:GNGBY) and Xcorporeal (OTCMKTS:XCRP) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Getinge and Xcorporeal, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Getinge11502.57
Xcorporeal0000N/A

Valuation & Earnings

This table compares Getinge and Xcorporeal's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Getinge$2.81 billion2.76$129.29 millionN/AN/A
XcorporealN/AN/AN/AN/AN/A

Getinge has higher revenue and earnings than Xcorporeal.

Risk and Volatility

Getinge has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Xcorporeal has a beta of 3.62, meaning that its stock price is 262% more volatile than the S&P 500.

Profitability

This table compares Getinge and Xcorporeal's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Getinge10.51%17.30%7.90%
XcorporealN/AN/AN/A

Insider & Institutional Ownership

0.0% of Getinge shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Getinge beats Xcorporeal on 6 of the 7 factors compared between the two stocks.

LivaNova (NASDAQ:LIVN) and Xcorporeal (OTCMKTS:XCRP) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends and earnings.

Institutional and Insider Ownership

89.1% of LivaNova shares are held by institutional investors. 0.5% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares LivaNova and Xcorporeal's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LivaNova-21.88%5.55%3.07%
XcorporealN/AN/AN/A

Earnings & Valuation

This table compares LivaNova and Xcorporeal's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LivaNova$1.08 billion3.65$-155,180,000.00$3.0826.42
XcorporealN/AN/AN/AN/AN/A

Xcorporeal has lower revenue, but higher earnings than LivaNova.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for LivaNova and Xcorporeal, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LivaNova04202.33
Xcorporeal0000N/A

LivaNova currently has a consensus target price of $69.3333, indicating a potential downside of 14.79%. Given LivaNova's higher probable upside, analysts plainly believe LivaNova is more favorable than Xcorporeal.

Risk & Volatility

LivaNova has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Xcorporeal has a beta of 3.62, meaning that its share price is 262% more volatile than the S&P 500.

Summary

LivaNova beats Xcorporeal on 7 of the 9 factors compared between the two stocks.


Xcorporeal Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Medtronic logo
MDT
Medtronic
2.7$123.90flat$167.03 billion$28.91 billion47.29
Sonova logo
SONVY
Sonova
0.9$56.74flat$18.40 billion$2.96 billion38.08Increase in Short Interest
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$177.07flat$16.26 billion$3.17 billion60.43
Masimo logo
MASI
Masimo
1.6$239.55flat$13.24 billion$937.84 million62.22Insider Selling
Getinge logo
GNGBY
Getinge
0.6$30.56flat$7.77 billion$2.81 billion25.25Upcoming Earnings
Analyst Upgrade
News Coverage
LivaNova logo
LIVN
LivaNova
1.5$81.37flat$3.96 billion$1.08 billion-18.92Analyst Report
News Coverage
CNMD
CONMED
1.6$130.45flat$3.78 billion$955.10 million-3,261.25
InMode logo
INMD
InMode
1.5$83.53flat$2.67 billion$156.36 million60.09Analyst Downgrade
Outset Medical logo
OM
Outset Medical
1.0$54.50flat$2.34 billionN/A0.00Analyst Upgrade
BioLife Solutions logo
BLFS
BioLife Solutions
2.1$33.59flat$1.12 billion$27.37 million-46.01Insider Selling
Increase in Short Interest
NTUS
Natus Medical
1.1$28.63flat$969.81 million$495.52 million-52.05
TransMedics Group logo
TMDX
TransMedics Group
1.6$29.13flat$797.29 million$23.60 million-20.81Increase in Short Interest
Gap Down
AxoGen logo
AXGN
AxoGen
1.5$19.42flat$791.79 million$106.71 million-30.83News Coverage
SMLR
Semler Scientific
1.2$110.00flat$738.87 million$32.77 million77.46Insider Selling
Decrease in Short Interest
News Coverage
ViewRay logo
VRAY
ViewRay
1.3$4.43flat$712.35 million$87.78 million-4.98
Stereotaxis logo
STXS
Stereotaxis
0.6$8.35flat$615.89 million$28.90 million-75.91
Cutera logo
CUTR
Cutera
1.3$30.78flat$547.36 million$181.71 million-17.01
Zynex logo
ZYXI
Zynex
1.8$15.19flat$529.45 million$45.47 million46.03
Edap Tms logo
EDAP
Edap Tms
1.3$9.06flat$264.03 million$50.23 million-151.00Increase in Short Interest
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$8.24flat$191.58 million$3.38 million-4.31Decrease in Short Interest
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$4.21flat$133.84 millionN/A0.00News Coverage
FONR
FONAR
1.1$17.98flat$117.84 million$85.69 million16.96
IRIDEX logo
IRIX
IRIDEX
0.9$7.41flat$115.01 million$43.45 million-13.47
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.22flat$97.26 millionN/A-1.61Increase in Short Interest
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.28flat$94.85 million$10,000.00-1.24Analyst Upgrade
Increase in Short Interest
electroCore logo
ECOR
electroCore
1.4$1.82flat$88.23 million$2.39 million-2.30Decrease in Short Interest
Electromed logo
ELMD
Electromed
1.8$10.09flat$87.13 million$32.47 million24.02Analyst Downgrade
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.5$17.56flat$40.58 million$1.50 million-1.00Increase in Short Interest
Fc Global Realty logo
FCRE
Fc Global Realty
0.5$0.10flat$38.87 million$40,000.000.00Gap Up
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.33flat$32.18 million$5.51 million-0.11High Trading Volume
Increase in Short Interest
Viveve Medical logo
VIVE
Viveve Medical
0.9$3.01flat$31.13 million$6.57 million-0.01
ReShape Lifesciences logo
RSLS
ReShape Lifesciences
0.6$4.40flat$27.14 million$15.09 million0.00Gap Up
PEYE
Precision Optics
0.4$1.62flat$21.49 million$9.92 million-16.20
Vaso logo
VASO
Vaso
0.9$0.09flat$17.02 million$75.75 million4.59News Coverage
Gap Up
STRR
Star Equity
0.1$3.21flat$15.80 million$114.18 million-1.02
GTHP
Guided Therapeutics
0.3$0.80flat$10.81 million$40,000.00-3.33Gap Up
Micron Solutions logo
MICR
Micron Solutions
0.3$3.01flat$10.12 million$17.50 million21.50Increase in Short Interest
NIMU
Non-Invasive Monitoring Systems
0.5$0.03flat$2.49 millionN/A0.00Upcoming Earnings
RSLSD
ReShape Lifesciences
0.4N/AN/A$1.94 million$610,000.000.00High Trading Volume
Nexeon MedSystems logo
NXNN
Nexeon MedSystems
0.7$0.55flat$1.12 millionN/A0.00
ARDMQ
Aradigm
0.0$0.05flat$764,000.00N/A0.00
MAGAA
Magna-Lab
0.7$0.58flat$678,000.00N/A3.19Gap Down
IMRIS logo
IMRSQ
IMRIS
0.5$0.01flat$364,000.00N/A0.00Gap Up
Echo Therapeutics logo
ECTE
Echo Therapeutics
0.5$0.03flat$356,000.00N/A0.00Gap Up
SCIE
SpectraScience
0.5$0.00flat$265,000.00N/A0.00Decrease in Short Interest
News Coverage
Gap Down
ULGX
Urologix
0.6$0.01flat$153,000.00N/A0.00Gap Up
AKSY
Aksys
0.0$0.00flat$0.00N/A0.00
Escalon Medical logo
ESMC
Escalon Medical
0.5$0.40flat$0.00$9.40 million-6.67Increase in Short Interest
Gap Down
HRTT
Heart Tronics
0.0$0.02flat$0.00N/A0.00High Trading Volume
Gap Up
IVVI
Ivivi Technologies
0.0$0.00flat$0.00N/A0.00High Trading Volume
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.